The global anti-allergic drugs market is expected to grow at a CAGR of around 6.8% from 2020 to 2027 and expected to reach the market value of around US$ 39.5 Bn by 2027.
The term “anti-allergy drug” refers to drugs that regulate the release and action of chemical mediators involved in allergic reactions, whether mediated by IgE (immediate or type I allergic reaction) or inflammatory mediators. Many anti-allergy drugs on the market today are classified into five types based on their mechanism of action: mediator-release inhibitors, histamine H1 antagonists, thromboxane A2 inhibitors, leukotriene antagonists, and Th2 cytokine inhibitors.
Big calls for "Allergy Shots" resulting in growth of global anti-allergic drugs market
Allergy shots are the most common and effective type of allergy immunotherapy. They are used to treat allergic conditions of the nose and eyes (allergic rhinoconjunctivitis), the ears (allergic otitis media), the lungs (bronchial asthma), and severe insect sting allergy. Many allergens, including trees, grass, weeds, mould, house dust, animal dander, and insect stings, are effectively treated with shots. According to the American College of Allergy, Asthma, and Immunology, there is little risk associated with allergy shots. There is also a slight risk of anaphylactic shock (severe allergic reactions) shortly after injection. As a result, allergic shots are administered in an allergist's office. Allergy shots are effective in treating allergic asthma. Allergy shots can help relieve the allergic reactions that cause asthma attacks, improving breathing and reducing the need for asthma medications.
Rising prevalence of allergic reactions upsurge the demand for anti-allergic drugs contributing overall growth of the market
When a patient's immune system reacts to a foreign substance known as an allergen, this is referred to as an allergy. Coughing, sneezing, hives, rashes, itchy eyes, a runny nose, and a scratchy throat may result from this reaction. It can cause low blood pressure, breathing difficulties, asthma attacks, and even death in severe cases. According to the Asthma and Allergy Foundation of America, more than 50 million Americans suffer from various types of allergies each year. Furthermore, allergies are the sixth leading cause of chronic illness in the United States. Allergic conditions are among the most common health problems affecting children in the United States. Hay fever was diagnosed in 7.7 percent of adults and 7.2 percent of children in 2018. Anaphylaxis to food is estimated to cause 30,000 emergency room visits in the United States each year. Such factors increase the global demand for anti-allergy medications.
Introduction of immunotherapy specifically sublingual immunotherapy boosts the anti-allergic drugs market globally
Immunotherapy may be used to treat some allergy patients. Immunotherapy is classified into two types. Allergy shots and sublingual immunotherapy are the two options (SLIT). SLIT is another method for treating certain allergies without the use of injections. Allergists administer small doses of an allergen under the tongue to patients. This exposure increases tolerance to the substance and alleviates symptoms. SLIT is a relatively safe and effective treatment for nasal allergies and asthma. SLIT tablets for dust mites, grass, and ragweed are currently available. While allergy shots are relatively safe, there is a risk of a severe, life-threatening allergic reaction, so they must always be administered in an allergist's office under the supervision of a medical professional. Researchers are looking into potential treatments for certain food allergies. Oral immunotherapy (OIT), SLIT, and other methods are among them. These studies are still in the early stages. They are not tried-and-true treatments. The studies are evaluating the treatments' safety and efficacy.
Combination therapy in anti-allergic drugs fuel overall growth of the market
Corticosteroids, which were first introduced in the 1970s, have different mechanisms of action but do not suppress histamine release; thus, they are commonly used in combination with antihistamines. The patent expiration of leading prescription antihistamines and corticosteroids is resulting in the introduction of more generic and over-the-counter (OTC) products into the anti-allergic therapeutic market. According to the American Academy of Family Physicians, one study that looked at the combination of corticosteroids and antihistamines, such as fluticasone and azelastine, found that this treatment combination was superior to either treatment alone in patients with moderate to severe allergic rhinitis. As a result, while patients should not begin therapy with more than one agent, combination therapy is an option for patients who have severe or persistent symptoms.
The global anti-allergic drugs market is segmented based on type of allergy, medication, and end-users. By type of allergy, the market is segmented as food allergy, skin allergy, indoor and outdoor allergies, insect allergy, drug allergies, latex allergy, and others. Based on type of medication, market is segregated as corticosteroids, antihistamines, epinephrine, decongestants, allergen immunotherapy, and among others. Based on end-users, the market is segmented as hospitals, clinics, ambulatory clinics, and others. Anti-histamines are further sub segmented into brompheniramine and cetirizine. Corticosteroids further sub segmented as dexamethasone. Decongestants further classified into phenylephrine.
Based on type of medication, corticosteroids are expected to gain reasonable market share for the global anti-allergic drugs market. By end-users, hospital segment holds dominant market share from the past and is predicted to continue similar trend of dominance in the coming years.
The anti-allergic therapeutics market is divided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is expected to hold a significant market share in the global anti-allergic drugs market during the forecast period. One of the major factors contributing to the global growth of anti-allergic drugs is the growing number of people who suffer from allergies. Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the coming years. The rapid development of health-care infrastructure is a major factor driving the growth of the global anti-allergic drugs market. Europe will have the world's second largest market share for anti-allergic drugs. The growing demand for immunotherapy treatment is exacerbating the growth of the anti-allergic drugs market.
The prominent players of the global anti-allergic drugs market involve Allergy Therapeutics, Allergan, Plc., Genentech, Inc., Collegium Pharmaceutical, McNeil Consumer Healthcare, Strides Pharma Science Limited, Allergopharma GmbH & Co. KG., and among others
Market By Type of Allergy
Indoor and Outdoor Allergies
Market By Medication
Market By End-Users
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Anti-allergic drugs market is expected to reach a market value of around US$ 39.5 Bn by 2027.
The anti-allergic drugs market is expected to grow at a CAGR of around 6.8% from 2020 to 2027.
Based on medication, corticosteroids segment is the leading segment in the overall market.
Combination therapy is one of the prominent factors that drive the demand for anti-allergic drugs market.
Allergy Therapeutics, Allergan, Plc., Genentech, Inc., Collegium Pharmaceutical, McNeil Consumer Healthcare, Strides Pharma Science Limited, Allergopharma GmbH & Co. KG., and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years